BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22693015)

  • 1. Histological variants of medulloblastoma are the most powerful clinical prognostic indicators.
    Massimino M; Antonelli M; Gandola L; Miceli R; Pollo B; Biassoni V; Schiavello E; Buttarelli FR; Spreafico F; Collini P; Giangaspero F
    Pediatr Blood Cancer; 2013 Feb; 60(2):210-6. PubMed ID: 22693015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
    von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
    Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
    Gajjar A; Chintagumpala M; Ashley D; Kellie S; Kun LE; Merchant TE; Woo S; Wheeler G; Ahern V; Krasin MJ; Fouladi M; Broniscer A; Krance R; Hale GA; Stewart CF; Dauser R; Sanford RA; Fuller C; Lau C; Boyett JM; Wallace D; Gilbertson RJ
    Lancet Oncol; 2006 Oct; 7(10):813-20. PubMed ID: 17012043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy.
    Rutkowski S; Gerber NU; von Hoff K; Gnekow A; Bode U; Graf N; Berthold F; Henze G; Wolff JE; Warmuth-Metz M; Soerensen N; Emser A; Ottensmeier H; Deinlein F; Schlegel PG; Kortmann RD; Pietsch T; Kuehl J;
    Neuro Oncol; 2009 Apr; 11(2):201-10. PubMed ID: 18818397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol.
    von Bueren AO; Friedrich C; von Hoff K; Kwiecien R; Müller K; Pietsch T; Warmuth-Metz M; Hau P; Benesch M; Kuehl J; Kortmann RD; Rutkowski S
    Eur J Cancer; 2015 Nov; 51(16):2434-43. PubMed ID: 26254812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors after extraneural metastasis of medulloblastoma.
    Mazloom A; Zangeneh AH; Paulino AC
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):72-8. PubMed ID: 20133080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and prognostic factors of radiation therapy for medulloblastoma.
    Rieken S; Mohr A; Habermehl D; Welzel T; Lindel K; Witt O; Kulozik AE; Wick W; Debus J; Combs SE
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e7-e13. PubMed ID: 21345611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome--a new clinical perspective.
    Garrè ML; Cama A; Bagnasco F; Morana G; Giangaspero F; Brisigotti M; Gambini C; Forni M; Rossi A; Haupt R; Nozza P; Barra S; Piatelli G; Viglizzo G; Capra V; Bruno W; Pastorino L; Massimino M; Tumolo M; Fidani P; Dallorso S; Schumacher RF; Milanaccio C; Pietsch T
    Clin Cancer Res; 2009 Apr; 15(7):2463-71. PubMed ID: 19276247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medulloblastoma variants and survival at a children's hospital.
    Craver R; Sandquist D; Nadell J; Velez M
    Fetal Pediatr Pathol; 2011; 30(1):53-9. PubMed ID: 21204667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medulloblastoma: experience of a single institution.
    Wolff JE; Huettermann U; Ritter J; Straeter R; Palm D; Ruebe C; Kraehling KH; Jürgens H
    Klin Padiatr; 1998; 210(4):234-8. PubMed ID: 9743958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
    Pizer BL; Clifford SC
    Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy).
    Vivekanandan S; Breene R; Ramanujachar R; Traunecker H; Pizer B; Gaze MN; Saran F; Thorp N; English M; Wheeler KA; Michalski A; Walker DA; Saunders D; Cowie F; Cameron A; Picton SV; Parashar D; Horan G; Williams MV
    Pediatr Blood Cancer; 2015 Dec; 62(12):2132-9. PubMed ID: 26274622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medulloblastoma in adults : A retrospective single institution analysis.
    Hadi I; Roengvoraphoj O; Niyazi M; Roeder F; Schüller U; Belka C; Nachbichler SB
    Strahlenther Onkol; 2018 Mar; 194(3):225-234. PubMed ID: 29147840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and outcomes of medulloblastoma in adults.
    Ang C; Hauerstock D; Guiot MC; Kasymjanova G; Roberge D; Kavan P; Muanza T
    Pediatr Blood Cancer; 2008 Nov; 51(5):603-7. PubMed ID: 18649371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.
    Min HS; Lee YJ; Park K; Cho BK; Park SH
    Acta Neuropathol; 2006 Jul; 112(1):13-20. PubMed ID: 16691420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and prognostic factors in a series of adults with medulloblastomas.
    Riffaud L; Saikali S; Leray E; Hamlat A; Haegelen C; Vauleon E; Lesimple T
    J Neurosurg; 2009 Sep; 111(3):478-87. PubMed ID: 19231932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea.
    Yoon JH; Park KD; Kang HJ; Kim H; Lee JW; Kim SK; Wang KC; Park SH; Kim IH; Shin HY
    World J Pediatr; 2017 Aug; 13(4):367-373. PubMed ID: 28550392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
    Gajjar A; Hernan R; Kocak M; Fuller C; Lee Y; McKinnon PJ; Wallace D; Lau C; Chintagumpala M; Ashley DM; Kellie SJ; Kun L; Gilbertson RJ
    J Clin Oncol; 2004 Mar; 22(6):984-93. PubMed ID: 14970185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infants with medulloblastoma: a single institution review of survival.
    Geyer R; Levy M; Berger MS; Milstein J; Griffin B; Bleyer WA
    Neurosurgery; 1991 Nov; 29(5):707-10; discussion 710-1. PubMed ID: 1961400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.